Evidence map›Paper›PMID 31601823›Full record

ArticleScientific reports2019

Galectin-3 orchestrates the histology of mesentery and protects liver during lupus-like syndrome induced by pristane.

F S Lemos, J X Pereira, V F Carvalho, E S Bernardes, R Chammas, T M Pereira, R S Carvalho, R Luisetto, M C El-Cheikh, S Calil-Elias and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

F S LemosPrograma de Pós-graduação em Ciências Aplicadas a Produtos para Saúde (PPGCAPS), Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
J X PereiraInstituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil.
V F CarvalhoLaboratório de Inflamação, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, Instituto Nacional de Ciência e Tecnologia - Neuroimunomodulação (INCT-NIM), Rio de Janeiro, Brazil.
E S BernardesCentro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares (IPEN), São Paulo, SP, Brazil.
R ChammasLaboratório de Oncologia Experimental e Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-0342-8726
T M PereiraLaboratório de Alvos Moleculares, Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brazil.
R S CarvalhoLaboratório de Alvos Moleculares, Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro, Brazil.
R LuisettoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
M C El-CheikhInstituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
S Calil-EliasPrograma de Pós-graduação em Ciências Aplicadas a Produtos para Saúde (PPGCAPS), Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
F L OliveiraPrograma de Pós-graduação em Ciências Aplicadas a Produtos para Saúde (PPGCAPS), Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil. felipe@histo.ufrj.br.
Universidade Federal do Rio de Janeiro · BRUniversidade Federal Fluminense · BRUniversity of Padua · ITFundação Oswaldo Cruz · BRInstituto de Pesquisas Energéticas e Nucleares · BRInstituto do Câncer do Estado de São Paulo · BRUniversidade Federal de Goiás · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galectin-3 (Gal-3) controls intercellular and cell-extracellular matrix interactions during immunological responses. In chronic inflammation, Gal-3 is associated with fibrotic events, regulates B cell differentiation and delays lupus progression. Gal-3 deficient mice (Lgals3

Indexed as

AnimalsDisease Models, AnimalFemaleFibrosisGalectin 3HepatitisHumansInjections, IntraperitonealLiverLupus Erythematosus, SystemicMacrophages, PeritonealMesenteryMiceMice, KnockoutTerpenesGalectin 3Lgals3 protein, mousepristaneTerpenes

Identifiers

PMID31601823
PMCPMC6786989
OpenAlexW2979976785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.